1. Home
  2. LSTA vs RNXT Comparison

LSTA vs RNXT Comparison

Compare LSTA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • RNXT
  • Stock Information
  • Founded
  • LSTA 1980
  • RNXT 2012
  • Country
  • LSTA United States
  • RNXT United States
  • Employees
  • LSTA N/A
  • RNXT N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSTA Health Care
  • RNXT Health Care
  • Exchange
  • LSTA Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • LSTA 31.2M
  • RNXT 31.6M
  • IPO Year
  • LSTA N/A
  • RNXT 2021
  • Fundamental
  • Price
  • LSTA $2.61
  • RNXT $1.15
  • Analyst Decision
  • LSTA Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • LSTA 1
  • RNXT 2
  • Target Price
  • LSTA $15.00
  • RNXT $6.50
  • AVG Volume (30 Days)
  • LSTA 66.3K
  • RNXT 195.7K
  • Earning Date
  • LSTA 02-27-2025
  • RNXT 03-31-2025
  • Dividend Yield
  • LSTA N/A
  • RNXT N/A
  • EPS Growth
  • LSTA N/A
  • RNXT N/A
  • EPS
  • LSTA N/A
  • RNXT N/A
  • Revenue
  • LSTA N/A
  • RNXT N/A
  • Revenue This Year
  • LSTA N/A
  • RNXT N/A
  • Revenue Next Year
  • LSTA N/A
  • RNXT N/A
  • P/E Ratio
  • LSTA N/A
  • RNXT N/A
  • Revenue Growth
  • LSTA N/A
  • RNXT N/A
  • 52 Week Low
  • LSTA $2.19
  • RNXT $0.77
  • 52 Week High
  • LSTA $4.20
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.17
  • RNXT 58.08
  • Support Level
  • LSTA $2.45
  • RNXT $1.32
  • Resistance Level
  • LSTA $2.74
  • RNXT $1.40
  • Average True Range (ATR)
  • LSTA 0.32
  • RNXT 0.11
  • MACD
  • LSTA -0.05
  • RNXT 0.00
  • Stochastic Oscillator
  • LSTA 16.48
  • RNXT 39.47

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: